During the past 12 months, Sonnet BioTherapeutics Holdings's average Total Assets Growth Rate was 10.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 69.80% per year.
During the past 5 years, Sonnet BioTherapeutics Holdings's highest 3-Year average Total Assets Growth Rate was 785.50%. The lowest was 69.80%. And the median was 427.65%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sonnet BioTherapeutics Holdings Total Assets Chart
Sonnet BioTherapeutics Holdings Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonnet BioTherapeutics Holdings (NAS:SONN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sonnet BioTherapeutics Holdings's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sonnet BioTherapeutics Holdings Total Assets Related Terms
Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SONN has been successfully added to your 